Head-To-Head Review: Avalon GloboCare (ALBT) & Its Competitors

Avalon GloboCare (NASDAQ:ALBTGet Rating) is one of 60 publicly-traded companies in the “Management consulting services” industry, but how does it compare to its competitors? We will compare Avalon GloboCare to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Earnings & Valuation

This table compares Avalon GloboCare and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Avalon GloboCare $1.39 million -$9.09 million -2.38
Avalon GloboCare Competitors $1.54 billion $108.15 million 13.35

Avalon GloboCare’s competitors have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Avalon GloboCare and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avalon GloboCare -955.48% -460.58% -97.43%
Avalon GloboCare Competitors -56.87% -79.82% -7.02%

Insider & Institutional Ownership

0.9% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 41.3% of shares of all “Management consulting services” companies are owned by institutional investors. 64.0% of Avalon GloboCare shares are owned by company insiders. Comparatively, 29.4% of shares of all “Management consulting services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Avalon GloboCare and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalon GloboCare 0 0 0 0 N/A
Avalon GloboCare Competitors 54 447 960 14 2.63

As a group, “Management consulting services” companies have a potential upside of 43.94%. Given Avalon GloboCare’s competitors higher probable upside, analysts plainly believe Avalon GloboCare has less favorable growth aspects than its competitors.

Volatility and Risk

Avalon GloboCare has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Avalon GloboCare’s competitors have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.


Avalon GloboCare competitors beat Avalon GloboCare on 9 of the 10 factors compared.

About Avalon GloboCare

(Get Rating)

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.